
Glaucoma Sales Update for 6 Months Ended 31 December 2021

Highlights

- **Solid growth in German market as a result of sales team expansion**
- **Training of surgeons in Europe in use of new generation canaloplasty device *iTrack™ Advance***
- **Continued growth in China due to sustained marketing and sales effort**

Nova Eye Medical Limited (ASX: EYE) (**Nova Eye Medical** or the **Company**), a medical technology company committed to advanced ophthalmic treatment technologies and devices, today announces that it expects to report global sales of A\$6.5 million of glaucoma surgical devices for the six months to 31 December 2021¹. This represents growth of 1.6% on the prior comparative period².

Nova Eye Medical Managing Director, Tom Spurling, commented:

*“We are pleased to report our expectation of growth in sales for our glaucoma surgical devices. This follows the successful execution of several initiatives to drive market awareness of our proprietary canaloplasty technology for the treatment of glaucoma, currently marketed as the *iTrack™* device.*

There were two major components to this outcome. First, solid growth in revenue in Germany due to investments in our commercial infrastructure, including a direct sales team. Second, continued growth in China as a result of the sustained marketing and sales effort of our local distribution partner.”

Other important initiatives in the glaucoma surgical device segment, include:

1. Pre-launch activities for the Company’s new generation canaloplasty device, *iTrack™ Advance*, commenced in Germany and other key markets in Europe in January via a surgical training program. The new *iTrack™ Advance* offers improved ease of use and will drive procedural adoption by a new, larger demographic of surgeons comprising comprehensive ophthalmologists. The *iTrack™ Advance* has a CE Mark. The global market value for glaucoma surgical devices is currently estimated at US\$610 million per year with 17% annual growth.

¹ Figures based on management accounts that have not been audited

² Measured in constant currency 1 July 2021 – 31 Dec 2021

2. To better align with the commercial availability of the *iTrack™ Advance* in CE cleared markets, the design and protocol of the MAGIC multi-center study was pivoted to include several European study sites. We now estimate study completion in mid-2023.

The Company expects to release the audited half-year results for the period ending 31 December 2021 the week commencing 14 February 2022.

This release dated 01 February 2022 has been authorised for lodgement to ASX by the Board of Directors of Nova Eye Medical Limited and lodged by Simon Gray, Company Secretary.

– ENDS –

Company

Tom Spurling
Managing Director
+61 417 818 658
tspurling@nova-eye.com

Media


Kate Hunt
Head of Marketing
+61 404 080 679
khunt@nova-eye.com

Investors

Mark Flynn
Investor Relations
+61 416 068 733
mflynn@nova-eye.com

ABOUT THE GLOBAL GLAUCOMA MARKET

Glaucoma is the leading cause of irreversible blindness and the second leading cause of blindness worldwide. The aging global population is driving glaucoma prevalence and provides a strong platform for business growth.



³ Market Scope 2021 Glaucoma Surgical Devices Report

⁴ Market Scope 2021 Glaucoma Surgical Devices Report based on sum of MIGS, Canal Surgery Devices and Glaucoma Tubes and Shunts Markets

ABOUT NOVA EYE MEDICAL

Nova Eye Medical Limited is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons in more than 100 countries globally, these technologies include iTrack™ minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The Molteno3® glaucoma drainage device platform is designed to enhance surgical utility and optimize clinical outcomes for long-term IOP control in cases of severe glaucoma. It also offers the benefit of a simplified and faster surgical procedure. With its sales headquarters based in Fremont, California, Nova Eye Medical is supported by a global network of more than 50 distribution partners. Manufacturing facilities are located in Fremont, California and Dunedin, New Zealand.

For additional information about Nova Eye Medical and its technologies, please visit:

www.nova-eye.com

The iTrack™ Advance has a CE Mark (Conformité Européenne) for the treatment of open-angle glaucoma and is currently available in selected markets in Europe and the Asia Pacific.

The iTrack™ has a CE Mark (Conformité Européenne) and 510(k) clearance in the United States for the indication of fluid infusion and aspiration during surgery, and for catheterization and viscodilation of Schlemm's canal to reduce intraocular pressure in adult patients with open-angle glaucoma. The iTrack™ is currently not 510(k) cleared for use with the ab-interno technique in the United States.